Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
NOVEL EGFR AND ALK DUAL INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2017/101803
Kind Code:
A1
Abstract:
The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.

Inventors:
LIU JING (CN)
LIU QINGSONG (CN)
JIANG TAOSHAN (CN)
WANG AOLI (CN)
WU JIAXIN (CN)
WU HONG (CN)
QI ZIPING (CN)
CHEN YONGFEI (CN)
ZOU FENGMING (CN)
WANG WENCHAO (CN)
ZHAO ZHENG (CN)
WANG LI (CN)
WANG BEILEI (CN)
Application Number:
CN2016/110033
Publication Date:
June 22, 2017
Filing Date:
December 15, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
PRECEDO PHARMACEUTICALS CO LTD (CN)
International Classes:
C07D401/12; A61K31/506; A61K31/5377; A61K31/551; A61P35/00; A61P35/02; C07D239/47; C07D239/48; C07D403/12; C07D409/12
Domestic Patent References:
WO2013169401A12013-11-14
Foreign References:
CN103501612A2014-01-08
CN104974140A2015-10-14
CN105085483A2015-11-25
Other References:
See also references of EP 3392245A4
Attorney, Agent or Firm:
SHANGCHENG & PARTNERS (CN)
北京尚诚知识产权代理有限公司 (CN)
Download PDF: